Welcome to our dedicated page for Cutera news (Ticker: CUTR), a resource for investors and traders seeking the latest updates and insights on Cutera stock.
Cutera, Inc. (symbol: CUTR) is a leading innovator in the field of medical aesthetics, specializing in the design, development, manufacturing, marketing, and servicing of energy-based aesthetic systems. Established in 1998 by experienced laser and optical engineers in Brisbane, California, Cutera has grown to become a trusted authority in face and body energy-based medical aesthetic technologies.
Cutera pioneered Nd:YAG technology and has continued to innovate, offering a premium portfolio of products that include Xeo®, truSculpt®, and excel V™. In 2014, the company expanded its product line with two significant additions: excel HR™, which provides high-speed, comfortable hair removal, and enlighten™, the industry's first system combining picosecond and nanosecond wavelengths.
With a presence in over 40 countries and direct operations in North America, France, Australia, Japan, and Hong Kong, Cutera is committed to meeting the evolving needs of the medical aesthetic community. Their solutions are designed to deliver better results, faster and safer than ever before.
The company markets its products under various trademarks, including Cutera, Acutip, Coolglide, Enlighten, Excel HR, Excel V, Genesis Plus, Pico-genesis, Titan, truSculpt, and Xeo. Cutera derives the majority of its revenue from the United States but maintains a strong international presence.
Recent achievements include the introduction of innovative products that have set new industry standards. Cutera's focus on research and development ensures that they remain at the forefront of the medical aesthetic technology market, continuously providing advanced solutions to practitioners worldwide.
For the latest updates and relevant information about Cutera's performance, events, and developments, stay tuned to Cutera's news section on StockTitan.
Cutera, Inc. (NASDAQ: CUTR), a leader in aesthetic solutions, has responded to a demand from Executive Chairman J. Daniel Plants for a special meeting of stockholders. This meeting seeks to remove the majority of the Board of Directors without cause. In response, Cutera's Board has formed a Special Committee of independent directors to review the demand. The Special Committee is committed to acting in the best interests of the company and its stockholders, and it will provide a formal recommendation soon. As of now, stockholders are not required to take any action. Wilson Sonsini and Sidley Austin LLP are serving as legal counsel to the Company and the Special Committee, respectively.
Cutera, a leading provider of aesthetic solutions, received a notice from Nasdaq on March 21, 2023, indicating non-compliance with listing rules due to late filing of its Form 10-K for the year ending December 31, 2022. The original due date was March 16, 2023. Cutera has 60 days from receipt of the notice to submit a compliance plan, with a potential extension until September 12, 2023, if accepted. The company is diligently working to file the Form 10-K as soon as possible. The notice does not impact current trading or listing status.
CUTERA, INC. (Nasdaq: CUTR) has unveiled an updated truBody brand, enhancing its marketing and patient experience through a new website, campaign, and social media presence. The brand refresh includes the renaming of key treatments: truSculpt® for fat reduction and truFlex™ for muscle toning, alongside the introduction of the Trim & Tone protocol, featuring one truSculpt and four truFlex sessions. This initiative aims to boost market visibility and improve patient outcomes, as highlighted by senior executives and practitioners emphasizing truBody's positive impact.
Cutera, Inc. (CUTR) reported Q4 and full-year 2022 financial results, showing consolidated revenue of $67.4 million in Q4, a 3% increase year-over-year. Full-year revenue reached $252.4 million, a 16% increase in constant currency. Notably, AviClear generated $4.5 million in revenue. However, the company reported a GAAP net loss of $82.3 million for 2022, significantly higher than a profit of $2.1 million in 2021. For 2023, Cutera forecasted revenue between $277 million and $292 million, indicating 10% to 16% growth.
Cutera, Inc. (CUTR), a provider of aesthetic and dermatology solutions, will announce its fourth quarter and full year 2022 financial results after market close on February 28, 2023. The management will discuss these results in a conference call at 1:30 p.m. PT the same day. Investors can join the call via phone or by accessing the webcast through Cutera’s website. Founded in 1998 and based in Brisbane, California, Cutera develops innovative products for medical practitioners to offer safe treatments. More information is available on their website.
Cutera, Inc. (CUTR) released preliminary financial results for the year ended December 31, 2022, expecting revenues between $252 million to $253 million, reflecting a growth of 15% to 16% year-over-year. This is lower than previous guidance of $255 million to $260 million. The final results will be disclosed on February 28, 2023, during a conference call. Additionally, Cutera management will be engaging with investors from January 10-12, 2023, at the Nasdaq offices in San Francisco.
Cutera, Inc. announced the pricing of $100 million in convertible senior notes due 2029 at a 4.00% interest rate. The notes will close on December 12, 2022, and include an option for initial purchasers to buy an additional $20 million. Proceeds are expected to be approximately $96.4 million, intended for general corporate purposes, including acquisitions and working capital. The initial conversion price is set at $58.35 per share. The company may redeem the notes after December 5, 2025, under specific conditions.
Cutera, Inc. (NASDAQ: CUTR) announced plans to offer $100 million in convertible senior notes due 2029 to qualified institutional buyers. The offering may include an additional $20 million at the initial purchasers' option. Proceeds will cover the costs of capped call transactions and fund general corporate purposes, including working capital, acquisitions, and potential stock repurchases. The notes are unsecured and will be convertible into cash or common stock. Notably, this offering aims to mitigate potential dilution of shares upon conversion.
Cutera, Inc. (CUTR) announced its response to a recent FDA inquiry regarding marketing materials related to its MyJuliet device. The company had previously removed all materials related to gynecological uses in 2019. However, a vestigial marketing piece was recently identified in an FDA Warning Letter, attributed to a third-party website that Cutera managed. Cutera is taking corrective actions to ensure compliance and has not promoted MyJuliet since 2019, with minimal sales. The company intends to exit this market segment while supporting its customers and complying with FDA guidance.
Cutera, Inc. (CUTR), a prominent provider of aesthetic and dermatology solutions, announced that CEO Dave Mowry and VP Greg Barker will speak at the Piper Sandler 34th Annual Healthcare Conference. The event is scheduled for November 30, 2022, at 2:00 PM ET, and will take place at the Lotte New York Palace Hotel in New York, NY. The session will also be available via webcast on Cutera's website, with a replay provided approximately one hour after the event concludes.
FAQ
What is the current stock price of Cutera (CUTR)?
What is the market cap of Cutera (CUTR)?
What does Cutera, Inc. specialize in?
When was Cutera, Inc. established?
What are some of Cutera’s key products?
Where is Cutera, Inc. headquartered?
In how many countries does Cutera have a presence?
What technology did Cutera pioneer?
Where does Cutera derive the majority of its revenue?
What is the significance of the product excel HR™?
What is unique about the enlighten™ system?
How does Cutera stay at the forefront of the industry?
